Tuesday, May 30, 2023


Biotechnology News Magazine

Neuraxpharm Completes its Presence in Benelux by Opening an Affiliate in Brussels to Cover Belgium and Luxembourg

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the establishment of Neuraxpharm Belgium to cover Belgium and Luxembourg, completing its presence in Benelux as it continues its expansion pathway in Europe.

Neuraxpharm’s expansion into Belgium adds an additional country to the growing list of more than 20 countries where Neuraxpharm is widely recognized and established. Neuraxpharm Belgium will be based in Brussels and will distribute and market prescription brand Buccolam® (midazolam), which is indicated for the emergency treatment of children and adolescents with epileptic seizures, and Célocurine® (suxamethonium chloride) available in hospitals, an adjuvant of general anesthesia, both of which are already available on the Belgian market.
Neuraxpharm Belgium will develop its existing portfolio and plans to launch specialty products from the two branded product portfolios it acquired from Sanofi in July 2022. All products will be available for neurologists and psychiatrists, both in retail market, in hospitals and in pharmacies, for patients in Belgium and Luxembourg.

Dr. Pierre-Hervé Brun will be Country Manager for Neuraxpharm Belgium, alongside his current role as Country Manager for Neuraxpharm France. With 30 years in the pharmaceutical industry, Dr. Brun brings extensive experience in business development, market access & commercial operations management. His experience will be invaluable as Neuraxpharm accelerates its goal to become a global leader in the CNS field in Europe. Neuraxpharm plans to expand its Belgium team to support the significant opportunities in the Belgian market.

Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, said: “We are delighted by this strong and positive start to 2023 as we continue our expansion across Europe and increase our geographical presence. This is an exciting opportunity as we enter a new market to provide high quality medical solutions to Belgian patients.”

Dr. Pierre-Hervé Brun, Country Manager of Neuraxpharm Belgium, added: “We are enthusiastic about this expansion as we further solidify Neuraxpharm as a key player in providing CNS treatment to patients and enhancing the wellbeing of those suffering from these disorders.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine